98 related articles for article (PubMed ID: 22753738)
21. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
22. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of cyclohexylamine and lysine salt of mafosfamide.
Abele R; Aapro MS; Haefliger JM; Alberto P
Cancer Chemother Pharmacol; 1986; 16(2):182-3. PubMed ID: 3512115
[TBL] [Abstract][Full Text] [Related]
24. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Estlin EJ; Yule SM; Lowis SP
Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
[TBL] [Abstract][Full Text] [Related]
25. Development of anti-cancer drugs.
Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
[TBL] [Abstract][Full Text] [Related]
26. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).
Kohn FR; Landkamer GJ; Sladek NE
Immunopharmacol Immunotoxicol; 1987; 9(2-3):163-76. PubMed ID: 3437102
[TBL] [Abstract][Full Text] [Related]
27. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M
Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
[TBL] [Abstract][Full Text] [Related]
28. [Preclinical data as basis for the design of clinical studies].
Fichtner I
Onkologie; 2008; 31 Suppl 2():34-8. PubMed ID: 18487867
[TBL] [Abstract][Full Text] [Related]
29. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
[TBL] [Abstract][Full Text] [Related]
30. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Dancey JE; Curiel R; Purvis J
Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
[TBL] [Abstract][Full Text] [Related]
31. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
32. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
34. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
35. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
36. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.
Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):221-5. PubMed ID: 12136944
[TBL] [Abstract][Full Text] [Related]
38. Mafosfamide: a new intra-CSF chemotherapy?
Chamberlain MC
J Clin Oncol; 2005 Oct; 23(30):7748-9; author reply 7749. PubMed ID: 16234539
[No Abstract] [Full Text] [Related]
39. CT-2584 (Cell Therapeutics).
Bonfil RD
Curr Opin Investig Drugs; 2001 Mar; 2(3):424-7. PubMed ID: 11575717
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.
Ehlers EM; Kühnel W; Wiedemann GJ
J Cancer Res Clin Oncol; 2002 Feb; 128(2):65-72. PubMed ID: 11862475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
